Rapport Therapeutics (RAPP) Other Accumulated Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Other Accumulated Expenses data on file, last reported at $144000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 55.56% year-over-year to $144000.0 in Q1 2026; TTM through Mar 2026 was $144000.0, a 55.56% decrease from a year earlier, with the FY2025 full-year figure at $6000.0, down 98.72% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $144000.0, up from $6000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for RAPP reached as high as $469000.0 in Q4 2024 and fell as low as $6000.0 in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $208666.7 across 4 years, with a median of $144000.0 in 2026.
• Across the five-year window, Other Accumulated Expenses soared 311.4% in 2024 and plunged 98.72% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $114000.0 in 2023, then jumped by 311.4% to $469000.0 in 2024, then plunged by 98.72% to $6000.0 in 2025, then surged by 2300.0% to $144000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $144000.0 in Q1 2026, $6000.0 in Q4 2025, and $104000.0 in Q3 2025.